Drugs / AFP464
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT00348699 | Jul 2006 → Jan 2013 | male breast carcinoma, ovarian carcinoma, primary peritoneal carcinoma, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00369200 | Jun 2006 → Jan 2011 | cancer of unknown primary site | National Cancer Institute (NCI) | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01233947 | May 2011 → Aug 2012 | breast neoplasm | Tigris Pharmaceuticals | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AFP464 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01233947 ↗ |
| Modality | Small molecule | — CHEMBL2007884 ↗ |
| Route | Intravenous | “Given IV” NCT00348699 ↗ |